Actinogen Medical LimitedASX: ACW

Actinogen receives $10.8m R&D tax incentive rebate from ATO

· Issued by Actinogen Medical Limited via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

The rebate will be used to repay a loan from Endpoints Capital, with the company confirming a strong cash position following this transaction. This funding is crucial as Actinogen approaches final results from its pivotal trial of Xanamem in Alzheimer's disease.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/actinogen-receives-dollar10.8m-randd-tax-incentive-rebate-from-ato

Release

ASX ANNOUNCEMENT Actinogen receives $10.8m R&D tax incentive rebate from ATO Sydney, 26 October 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to 1 announce that it has received a research and development tax incentive (RDTI) rebate of $10,838,793 (including interest)...

Actinogen Medical Limited on 6ix

Earlier from Actinogen Medical

Later from Actinogen Medical

All Actinogen Medical news releases